Conditions: Lymphoma, T-Cell, Cutaneous
Keywords: CTCL Cutaneous T-Cell Lymphoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL.

Detailed description:

Arms:
arm 1: placebo for SHAPE (SHHP-141) topical gelled solution arm 2: SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly arm 3: SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly arm 4: SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly

Interventions: intervention 1: placebo for SHAPE (SHP-141) intervention 2: SHAPE (SHP-141) 0.1% BID intervention 3: SHAPE (SHP-141) 0.5% BID intervention 4: SHAPE (SHP-141) 1.0% BID
Intervention descriptions: intervention 1: topical gelled solution intervention 2: topical gelled solution intervention 3: topical gelled solution intervention 4: topical gelled solution

Protocol document: